Evaluating Pembrolizumab, Bevacizumab, and Oral Metronomic Cyclophosphamide in Heavily Pretreated Platinum-Resistant Ovarian Cancer: Real-World Outcomes and Clinical Implications
Posted innews OB/GYN & Women's Health Oncology

Evaluating Pembrolizumab, Bevacizumab, and Oral Metronomic Cyclophosphamide in Heavily Pretreated Platinum-Resistant Ovarian Cancer: Real-World Outcomes and Clinical Implications

This study assesses the efficacy and safety of pembrolizumab combined with bevacizumab and oral metronomic cyclophosphamide in heavily pretreated platinum-resistant ovarian cancer patients, showing modest disease control with manageable toxicity in a real-world setting.
Bevacizumab and Fractionated Stereotactic Radiotherapy: A Synergistic Breakthrough for Extensive Brain Metastases in NSCLC
Posted innews Oncology Radiology

Bevacizumab and Fractionated Stereotactic Radiotherapy: A Synergistic Breakthrough for Extensive Brain Metastases in NSCLC

The GASTO-1053 phase II study demonstrates that combining bevacizumab with fractionated stereotactic radiotherapy significantly improves intracranial progression-free survival (18.3 months) and quality of life for NSCLC patients with extensive brain metastases, providing a safe, effective alternative to whole-brain radiotherapy.